- Bristol-Myers Squibb (BMY +0.2%) expects a timely sign-off from the European Commission (EC) regarding its takeover of Celgene (CELG +0.5%), adding that the conclusion of the EC’s Phase 1 review is set for July 29.
- BMY has agreed to divest CELG’s Otezla (apremilast) in order to receive a timely thumbs-up in the U.S.
Date: July 29, 2019
Source: <span style=”color: #000000;”><a style=”color: #000000;” href=”https://seekingalpha.com/news/3480406-bristol-myers-confident-time-ok-celgene-deal-europe” target=”_blank” rel=”noopener noreferrer”>Seeking Alpha</a></span>
